After Divestiture, FTC To Allow Drug Acquistion
The U.S. Federal Trade Commission has given the green light to Actavis Group's acquisition of Abrika Pharmaceuticals, Inc., but only if the companies sell the rights to a blood pressure drug....To view the full article, register now.
Already a subscriber? Click here to view full article